Overdose Deaths in the United States: Research on Trends, Causes, and Response

Drug overdose deaths in the United States reached an all-time high of approximately 111,000 deaths in 2023, according to provisional data from the Centers for Disease Control and Prevention, continuing an upward trend that has persisted for more than two decades with only brief interruptions. The crisis has evolved through multiple distinct phases, from prescription opioid overdoses in the 2000s, to heroin overdoses in the 2010s, to the current dominance of synthetic opioids, particularly illicit fentanyl and its analogs. Research on the drivers of these trends, the populations most affected, and the interventions with the strongest evidence for reducing deaths is essential context for policy responses. Fentanyl and its analogs have become the primary drivers of overdose mortality in the current phase of the crisis. Illicit fentanyl, which is produced primarily in clandestine laboratories and distributed through drug supply chains, is approximately 50 to 100 times more potent than morphine and is now detected in the drug supply across all major drug categories, not only heroin and prescription opioids but also stimulants such as methamphetamine and cocaine. Research on contamination of the drug supply finds that many overdose deaths involve individuals who did not knowingly use opioids but consumed a stimulant or other drug containing fentanyl. This supply-side contamination creates overdose risk for people who have no opioid tolerance. Geographic patterns of overdose mortality have shifted significantly. What began primarily as an epidemic affecting white rural and suburban communities has broadened to affect Black, Latino, and Indigenous communities at higher rates, driven in part by the contamination of stimulant supplies with fentanyl and in part by longstanding structural barriers to treatment access in communities of color. Research on racial disparities in overdose mortality documents widening gaps in some states and regions, underscoring that the current phase of the crisis is not confined to the populations most prominent in early coverage. The relationship between overdose deaths and the broader opioid supply is complex. Prescription monitoring programs, which track opioid prescriptions to reduce overprescribing and doctor shopping, and restrictions on opioid prescribing have reduced prescription opioid supply. Research finds that these supply-side interventions contributed to the shift from prescription opioid to heroin and then to illicit fentanyl use among people with opioid use disorder, as individuals who could no longer access prescription opioids sought alternatives in the illicit market. This substitution pattern illustrates the importance of ensuring that treatment access expands alongside supply restrictions, to provide an alternative for individuals with established opioid use disorder. Naloxone distribution is one of the most clearly evidence-based overdose prevention strategies. Naloxone reverses opioid overdose by displacing opioids from brain receptors, rapidly restoring breathing in someone who has stopped breathing due to overdose. Research on community naloxone distribution programs finds that they reduce overdose mortality in the communities they serve. The FDA's approval of over-the-counter naloxone in 2023 removed a significant barrier to access, allowing sale at pharmacies without a prescription. Research on naloxone access finds that cost remains a barrier for some community members even when prescriptions are not required. Fentanyl test strips, which allow people to test drugs for fentanyl presence before using them, are a harm reduction tool that research supports as effective at reducing overdose risk among people who use drugs. Studies find that knowledge of fentanyl presence changes drug use behavior in ways that reduce overdose risk, including reducing use amount, having naloxone available, and avoiding use alone. Several states have removed fentanyl test strips from drug paraphernalia laws that previously made their distribution illegal, and research on these policy changes is tracking effects on overdose rates. Medication for opioid use disorder remains the most effective treatment for preventing overdose mortality among people with opioid use disorder. Research on buprenorphine and methadone finds dramatic reductions in overdose mortality, with studies finding that patients engaged in medication treatment have overdose mortality rates 50 to 80 percent lower than those not in treatment. Despite this evidence, the majority of people with opioid use disorder who could benefit from medication do not receive it, driven by access barriers including provider shortages, stigma, regulatory requirements, and insurance coverage gaps. Safe supply programs, which provide pharmaceutical grade opioids to individuals with severe opioid use disorder as an alternative to illicit supply, are implemented in several Canadian provinces and are being evaluated in research. The theoretical rationale is that providing a supply of known dosage and composition eliminates the fentanyl contamination risk that drives much overdose mortality. Early Canadian research on safe supply programs finds reductions in illicit drug use among participants and improvements in quality of life, though the evidence base is still limited and the approach remains controversial. The public health response to overdose deaths requires a combination of strategies operating simultaneously: expanding medication treatment access, distributing naloxone widely, supporting harm reduction including test strip access and supervised consumption, addressing the supply chain of illicit fentanyl, and attending to the social conditions including poverty, trauma, and lack of opportunity that drive substance use disorder. Research provides guidance on which approaches have the strongest evidence, but the scale of investment and political will required to implement them comprehensively has not yet been mobilized to meet the scale of the crisis.